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Tumor microenvironment is characterized by a consistent reduction in oxygen and blood-
borne nutrients that significantly affects the metabolism of distinct cell subsets. Immune 
cells populating malignant lesions need to activate alternative pathways to overcome 
tumor-prolonged nutrient deprivation. In particular, the metabolic switch occurring in 
transforming tissues dramatically impacts on tumor-infiltrating T cell biology. Remarkably, 
the recruitment and activation of T cell within cancers are instrumental for effective 
antitumor response. Therefore, T cell metabolic adaptation acts as crucial checkpoint 
hijacked by tumors to dampen antitumor immunity.
Keywords: tumor microenvironment, T lymphocyte activation, immune escape, reactive nitrogen species, 
immunotherapy
inTRODUCTiOn
Cancers are not mere collections of relatively homogenous tumor cells, but they rather form a 
sort of crowded organ composed of different cell populations supporting malignant nourishment 
and progression. To ensure tumor growth and immune evasion, the stromal component of tumor 
mass undergoes numerous metabolic adaptations, reprograming the mode of energy generation 
(1). Metabolic reprograming of cancer and stromal cells fulfils the urgent need for energy supply 
to support tumor cell proliferation and progression, thus representing one additional hallmark of 
cancers (2). Notwithstanding, the first observations of metabolic alterations in cancer cells date back 
to the early 90s, when Otto Warburg found that cancer cells, regardless of oxygen tension, prefer to 
metabolize glucose by glycolysis.
Albeit more rapid than oxidative phosphorylation, anaerobic glycolysis (fermentation) is less 
efficient in ATP generation and, reducing lactate, contributes to the accumulation of metabolites 
that promote immunosuppression (3). The glycolytic switch of tumor cells, also known as “Warburg 
effect” offers a valuable tool for diagnosis, staging, and monitoring therapy response in many cancers, 
and it accounts for the physiological basis for positron emission tomography (PET) in clinical oncol-
ogy (4). In addition to the Warburg effect, both tumor and stromal cells exploit other catabolic routes 
aimed at amino acid conversion into more affordable energetic products, as well as change in lipid 
metabolism (5).
This metabolic adaptation works indeed as crucial checkpoint hijacked by tumors to dampen 
antitumor immunity. Solid tumors build up a forbidding environment characterized by a consistent 
reduction in O2 and blood-borne nutrients. The paucity of appropriate nutrients represents, so far, a 
limiting step for the effectiveness of antitumor immune responses since T cells infiltrating malignant 
tissues need to face the tumor hostile environment to exert their functions.
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MeTABOLiC ADAPTATiOnS OF T CeLLS 
wiTHin THe TUMOR
Tumor-infiltrating immune cells include cell subsets belonging 
to both the innate and the adaptive arms of the immune system. 
The immune setting within the locoregional tumor microenvi-
ronment significantly dictates cancer fate. A strong lymphocytic 
infiltration, so far, has been reported to be associated with good 
clinical outcome in different human tumors (6). The intratumoral 
activation of T cell responses may result in the control of tumor 
growth and spreading in some cancers, such as in melanoma (7). 
In fact, recent advances in cancer immunotherapy based on the 
clinical exploitation of monoclonal antibodies targeting T cell-
immune checkpoints, such as PD-1 (8) and CTLA4 (9), clearly 
confirmed the requirement of an efficient T cell activation for an 
effective antitumor response. CD4+ and CD8+ T lymphocytes are 
fundamentally able to recognize tumor antigens and to activate 
their effector programs even within transformed tissues.
T cells, experiencing the metabolic framework of growing 
tumors, need to activate distinct pathways to accomplish their 
functional requirements. Nonetheless, tumors impose several 
limitations to dampen T cell immunity, and among these, the 
control of nutrient availability and handling represents one cru-
cial process. In growing tumors, where neoplastic cells proliferate 
at a very high rate, the deprivation of particular nutrients, such 
as glucose or amino acids, from the environment dramatically 
hinders T cell functions. Basically, T cell metabolic reprograming 
relies upon the activation of distinct transcriptional and signaling 
pathways that are now beginning to be elucidated.
Metabolic reprograming accounting for the increasing energy 
demand is crucial for the triggering of T cell effector functions. The 
transition from the “energy-saving” oxidative metabolism – typi-
cal of naïve/memory T cells – to the primarily biosynthetic and 
anabolic metabolism of effector T cells requires a substantial 
uptake of nutrients from the environment (10, 11). This is clearly 
connected to the urgency of an activated T cell to support its 
own duties, such as cell proliferation, cytotoxicity, and adaptive 
cytokine production. To do that, with respect to quiescent cells, 
effector T lymphocytes switch the metabolism toward aerobic 
glycolysis increasing the uptake of glucose and glutamine from 
the outside and the consumption of oxygen (12). In particular, 
the engagement/disengagement of aerobic glycolysis represents 
a crucial mechanism controlling T cell effector status by means 
of the posttranscriptional regulation of IFN-γ production (13). 
Furthermore, the activation of PD-1 signal, which is linked to 
T cell exhaustion, inhibits the uptake and utilization of glucose 
and glutamine increasing the rate of fatty acid β-oxidation (FAO) 
in T cells (14). A drop of glucose level within tissues leads T 
cells to enter a dormant “anergy” state to spare energy (15) or to 
preferentially activate autophagy as survival mechanism (16) to 
counteract nutrient insufficiency. Activated T cells upregulate the 
surface expression of key nutrients receptors, such as the amino 
acid and glucose transporters, triggering the hypoxia-inducible 
factor-α (HIF1-α), c-Myc, and the PI3K/Akt/mTOR (the mam-
malian target of rapamycin) (17, 18), which play a pivotal role in 
energetic adaptations of both cancer and immune cells (19).
HIF1-α is a transcriptional factor that is upregulated when 
oxygen tension decreases. In normoxic conditions, HIF1-α is 
constantly degraded by the proteasome complex; conversely, 
during hypoxia, it is stabilized and regulates the expression of 
angiogenic and tissue remodeling factors (20), together with 
enzymes involved in the commitment to glycolysis. Upon activa-
tion, HIF1-α promotes the expression of lactate dehydrogenase, 
pyruvate dehydrogenase kinase PDK1 (21), and several glycol-
ysis-related genes, such as GLUT1 and PFKFB3 (22), with the 
consequence of increasing glucose uptake and glycolysis, reduc-
ing pyruvate flux into the TCA cycle, oxidative phosphorylation, 
and oxygen consumption (20). Interestingly, it has been recently 
reported that HIF-1α represents a crucial metabolic checkpoint 
for the differentiation of either Treg or Th17 cells (23). Commonly 
associated with Tregs, the CD4 Th17 cell subset has increasingly 
gained attention in cancer immunity.
In combination with HIF1-α, the oncogene c-Myc also activates 
the expression of glucose transporters, PDK1 and lactate dehy-
drogenase A (LDHA), which is responsible for enhancing glucose 
influx and glycolysis. Moreover, c-Myc induces the expression of 
glutamine transporters and glutaminase1 for glutaminolysis (24). 
It has been reported that activated T cells exploit a non-canonical 
Myc-dependent pathway coupling glutaminolysis to polyamine 
biosynthesis in order to sustain cell growth and proliferation in 
both pathological and physiological situations (25).
mTOR is a downstream target of the PI3K–AKT signaling and 
has been demonstrated to enhance the expression of HIF1-α in 
immune cells recruited at the tumor lesion (26).
In tumours, mTOR activation promotes glycolysis by enhanc-
ing (HIF1) activity; additionally it sustains fatty acid and protein 
synthesis thus supporting the survival and functions of both 
malignant and pro-tumoural immune cells of (27, 28). Within 
solid tumors, mTOR activation tunes the balance between effec-
tor versus memory CD8 T cells by regulating the expression of the 
transcription factor T-bet (29).
An increased AMP:ATP ratio induces the activation of the 
energy sensor AMPK, which plays a key, but still controversial, 
role in T cell antitumor immunity. AMPK activation in T cells may 
resemble its role in tumor cells, where it controls cell viability and 
proliferation under poor nutrient conditions (30). Additionally, 
T cells may exploit this nutrient sensor to rapidly face glucose 
limitation in the environment. In this regard, it has been recently 
reported that in vivo the AMPK signaling pathway regulates Ifng 
mRNA translation and the glutamine-dependent mitochondrial 
metabolism in T cells (31). Moreover, recent findings showed 
that the selective deletion of AMPK in T cells decreases IFNγ 
and Granzyme B production in intratumoral CD8+ T cells (32).
In main contrast to effector T cells that metabolically suffer the 
tumor nutrient landscape, other T cell subsets, such as T regula-
tory cells (Tregs), feel comfortable with the very same environment. 
This is probably due to the abundance of growth factors (such 
as transforming growth factor-β) (33) and chemokines (such as 
CCL22) (34) promoting Treg differentiation and recruitment. The 
presence of Tregs in solid tumors essentially correlates with poor 
prognosis (35). In particular, in ovarian cancer, a higher CD8+ T 
cells/Treg cells ratio associates with a particularly favorable clinical 
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outcome (34). Nonetheless, Treg contribution in the context of 
chronically inflamed tissues, such as in colorectal cancer (CRC), 
remains controversial. Discordant evidence in patients with CRC 
support, so far, the notion that Treg infiltration and accumulation 
in cancerous tissues may play either a negative (36, 37) or positive 
(38, 39) predictive role for patient survival. Metabolically, Tregs do 
not require high rate of glucose consumption and usually express 
low level of the Glut1 transporter (40). Natural and Inducible 
Tregs are primarily oxidative and metabolize pyruvate through the 
TCA cycle. They preferentially utilize lipid beta-oxidation and 
present high levels of activated AMPK, which is usually active 
in starved-fed conditions (41, 42). Furthermore, it has been 
reported that several intratumoral metabolic leftover as lactate 
and kynurenine support Treg differentiation while suppressing T 
cell cytotoxic activity (43). The generation of Treg cells in vivo is 
dependent on the aryl hydrocarbon receptor (AHR)-mediated 
induction of IDO1 and kynurenine. AHR is ligand-activated 
transcription factor, which is chronically activated in aggressive 
tumors. Therefore, in contrast to T effector cells, Tregs feel com-
fortable in the nutrient-restrictive tumor microenvironment, 
where they can efficiently active immunosuppressive pathways. 
Additionally, tumor-derived lactate polarizes immune responses 
toward a Th17/Th23 phenotype (3, 44).
TUMOR MeTABOLiSM DRiveS T CeLL 
DYSFUnCTiOn
Tumor progression is characterized by a tangled network 
of relationships among different cell types that collectively 
exploit a metabolic reprograming and mutually influence their 
functionality and, in particular, T cell functions. Because of 
the Warburg effect and high glucose consumption by cancer 
cells, tumor microenvironment shows reduced extracellular 
concentration of glucose (45). As a consequence of glucose dep-
rivation, tumor-infiltrating T cells decrease aerobic glycolysis 
and generation of the phosphoenolpyruvate (PEP) metabolite 
involved in TCR-dependent activation of Ca2+ and NFAT 
signaling, thus losing their antitumoral effector functions (46). 
Moreover, lactate accumulation in the microenvironment has 
been shown to affect T cell activation by impairing lactic acid 
secretion and disturbing metabolism. In detail, tumor acidosis 
is accompanied by the suppression of proliferation and cytokine 
production in cytotoxic T cells (CTLs) and finally inhibits CTL 
cytotoxic activity (47). Acidification of tumor microenviron-
ment dramatically impairs cytotoxic T cell proliferation and 
function (48), though it does not affect Tregs (41), inhibits 
monocyte-derived DC differentiation and activation, and is 
positively correlated with radioresistance (49). Accelerated fer-
mentation, generating high level of lactate, constitutes indeed 
a marker for metastases and correlates with poor prognosis 
(50). Also hypoxia represents a hindrance to T cell antitumor 
responses. HIF-1α has been shown to upregulate the expression 
of PD-1 ligand on cancer cells, thus inhibiting T cell-mediated 
cytotoxicity (51). Beyond glycolysis, amino acid metabolism 
represents a crucial process in tumor progression. In particular, 
l-arginine and tryptophan catabolism have been demonstrated 
to be dysregulated in cancers (5, 52).
l-Arginine metabolism is strictly dependent on the activity of 
the enzymes, nitric oxide synthase (NOS) and arginase (ARG). 
While NOS oxidizes arginine to citrulline and nitric oxide (NO), 
arginase hydrolyzes arginine into ornithine and urea. Several 
reports have showed the expression of the inducible isoform 
of NOS enzyme (iNOS) in human colon cancers, ovarian and 
prostate cancers, melanoma, and other malignant lesions, 
including the hematological ones (53). Similarly, ARG activity 
is upregulated in colon, breast, lung, and prostate cancer (54), 
and ARG1 is associated with M2 polarized, protumoral TAMs 
(55). The activation of both enzymes generates high levels of NO 
capable of either promoting or inhibiting tumor progression or 
metastasis, depending on the local concentration and duration 
of exposure, cellular sensitivity and hypoxia/re-oxygenation 
process within tumor microenvironment (48). Additionally, 
NO produced by iNOS may rapidly react with reactive oxygen 
species within the tumor lesion and produce reactive nitrogen 
species (RNS) such as peroxynitrite, which is very toxic for many 
cells, and in particular for T cells. Peroxynitrite induces apoptotic 
cell death in lymphocytes by interfering with protein tyrosine 
phosphorylation via nitration of tyrosine residues (56) or by 
nitrating the voltage-dependent anion channel, a component of 
the mitochondrial permeability transition pore (57). Although 
solid tumors are characterized by lymphocyte infiltration, tumor-
infiltrating lymphocytes frequently are unable to kill autologous 
tumor cells, experiencing an anergic/tolerant state (58, 59). 
Importantly, we have previously shown the presence of high levels 
of nitrotyrosines in both cancer specimens and tumor-infiltrating 
lymphocytes (60). As a consequence of high rate of RNS produc-
tion, the tumor microenvironment is not suitable for T cell func-
tions, and indeed a number of reports indicate that peroxynitrite 
negatively affects T-cell-mediated immunity within the tumor 
(61) and that tumor-infiltrating lymphocytes have defects in both 
signal transduction and effector killing capacity (62).
Unlike normally responsive lymphocytes in healthy tissue and 
peripheral blood, tumor-infiltrating lymphocytes are not activated 
locally by powerful signals acting either on TCR or downstream 
signaling pathways. We have previously reported that this dormant 
state is dependent on the enhanced intratumoral metabolism of 
l-arginine, because the simple addition of arginase and NOS-
specific inhibitors was sufficient to rouse CTLs, activate them, 
and start a number of events leading to cytolytic granule polariza-
tion and killing of cognate targets (60). Furthermore, high and 
prolonged exposure to RNS has been demonstrated to modulate 
tyrosine phosphorylation of several proteins, such as the CD3ζ 
chain of the TCR complex, and release of Ca2+ from intracellular 
stores, thus promoting downregulation of membrane receptors, 
such as CD4, CD8, and chemokine receptors from T cells (63). 
Moreover, RNS dampen antitumor immunity by generating post-
translational modifications – nitration and nitrosylation – of key 
proteins for T cell activation (61) and recruitment to the tumor 
site (64). Post-translational modifications of chemokines and 
chemokine receptors constitute, in fact, another mechanism cho-
sen by tumor to promote local immune dysfunction and prevent 
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effective response. We previously demonstrated that intratumoral 
nitration/nitrosylation of the chemokine CCL2 plays a crucial 
role in antitumor immunity, since RNS-modified CCL2 restrains 
T lymphocytes to the stroma at the border of neoplastic lesions, 
preventing their infiltration to the tumor core (64). According 
to this, preconditioning of tumor microenvironment with drugs 
FiGURe 1 | Tumor microenvironment shapes T cell immunity. (1) Activated T lymphocytes switch the metabolism toward aerobic glycolysis, increasing the 
uptake of glucose and glutamine from the outside and the consumption of oxygen. T cells, once reached the tumor site, need to face a hostile environment, which is 
characterized by hypoxia and nutrient deprivation. Distinct pathways regulate T cell metabolism within the tumor microenvironment. In particular, the drop of glucose 
level leads T cells to enter an (2) anergy state or to activate autophagy. Moreover, (3) c-Myc and the PI3K/Akt/mTOR pathways play a pivotal role in the energetic 
adaptation of T cells within transforming tissues. Tumor hypoxia sustains the activation of the transcription factor HIF-1α. HIF-1α represents a crucial metabolic 
checkpoint for (4) the differentiation of either Treg or Th17 cells, and (5) it has been shown to upregulate the expression of PD-1 ligand on cancer cells. Remarkably, 
amino acid metabolism in tumors significantly impacts on T cell functions. Indeed, (6) the activation of both NOS and arginase enzymes in transforming tissues 
generates high levels of NO that rapidly react with ROS to generate RNS. (7) High and prolonged exposure to RNS promotes the downregulation of key proteins for 
T cell activation, such as the CD3ζ chain, CD25, CD28, and CD62L. Additionally, RNS induces the release of Ca2+ from intracellular stores, thus provoking a 
reduction in the expression of membrane receptors, such as CD4, CD8, and CXCR4. Moreover, (8) RNS-modified CCL2 restrains T lymphocytes to the stroma at 
the border of neoplastic lesions, preventing their infiltration to the tumor core. Tryptophan deprivation within the tumor microenvironment is mainly caused by the 
accelerated activity of the IDO enzyme. (9) The drop in tryptophan availability synergizes with the local accumulation of kynurenine and its derivatives to efficiently 
inhibit the proliferation and activation of T cells.
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impairing nitration induces massive T cell recruitment to tumor 
core and thus increases the efficacy of a T cell-based immuno-
therapy approach (64). Beyond this, alteration of l-arginine 
catabolism within tumors concomitantly causes local depletion 
of the amino acid (65). Deficiency in arginine availability affects 
protein synthesis in activated T cells, provoking a reduction in 
the expression of CD3ζ chain (66), activation markers, such as 
CD25, CD28, and CD62L, and has been shown to impair T cell 
proliferation and cytokine production (67).
Importantly, local depletion of another amino acid, trypto-
phan, alters T cell activity causing their anergy (68). Tryptophan 
deprivation within the tumor microenvironment is the result 
of the accelerated catabolism of the amino acid by the enzyme 
indoleamine 2,3-dioxygenase (IDO), which converts tryptophan 
to kynurenine and generates NAD. Although IDO enzymes are 
intracellular and not secreted, the metabolic effects of IDO are 
not locally confined to the IDO-expressing cells, but they rather 
involve neighboring cells that may sense and respond to the 
reduced availability of tryptophan and to secreted kynurenine 
metabolites (68). Importantly, although IDO activity may cause 
a significant decrease in tryptophan availability in vitro, a similar 
effect in  vivo, where tryptophan concentration is 50–100  mM 
and a rapid diffusion from neighboring tissues is reasonably 
expected, has not been demonstrated so far (69). Therefore, even 
though the drop in tryptophan availability may not be sufficient 
to induce strong immunosuppressive effects, it may synergize 
with local accumulation of kynurenine and its derivatives to 
efficiently inhibit the proliferation and activation of immune cells 
(70). Based on studies examining serum levels of tryptophan and 
kynurenine, IDO appears to be chronically activated in patients 
with cancer, and IDO activation correlates with more extensive 
disease (71). IDO positivity has been indeed demonstrated in 
human tumors of different histology, such as colon and ovarian 
cancers, melanoma, and leukemia (72), and it is expressed by 
tumor cells (73), endothelial cells (74), and infiltrating immune 
cells, mainly APCs, DCs, and TAMs contributing to immune 
suppression (68, 75). Further, IDO-positive tumors have been 
demonstrated an impairment of T cell functions, since trypto-
phan shortage in the extracellular space induces T cell anergy 
and apoptosis (76). It has also been reported that antigen-specific 
cytotoxic T cells do not accumulate in the presence of IDO 
expressing tumor cells, but this tolerogenic process may be 
overcome, in mice, by the administration of the competitive IDO 
inhibitor 1MT, which is a tryptophan analog (77). Additionally, 
the administration of the small molecule, INCB024360, 
blocking IDO enzymatic activity in murine pancreatic ductal 
adenocarcinoma significantly inhibits tumor growth in a 
lymphocyte-dependent manner (78).
COnCLUDinG ReMARKS
Metabolic reprograming of cancer and stromal cells in the 
tumor microenvironment is instrumental to meet the urgent 
need for energy supply to support tumor cell proliferation 
and progression, as well as immune evasion. The paucity of 
appropriate nutrients represents a limiting step for the effec-
tiveness of antitumor T cell responses since T cells infiltrating 
malignant tissues need to face the tumor hostile environment 
to exert their functions (Figure 1). The deprivation of glucose 
and amino acids from the environment dramatically hinders 
T cell functions since it concomitantly induces the accumula-
tion of toxic catabolic by-products. In this context, amino 
acid metabolism, and in particular l-arginine and tryptophan 
catabolism, represents a crucial process in tumor progression 
and immunity. The accumulation of RNS, dependent on the 
enhanced intratumoral metabolism of l-arginine within the 
tumor microenvironment, negatively affects T-cell-mediated 
immunity since it induces a dormant state in tumor-infiltrating 
lymphocytes, which have defects in signal transduction, migra-
tion, and effector killing capacity. Nonetheless, the adminis-
tration of drugs impairing nitration positively influences T 
cell activation and cytotoxic activity and induces a massive 
T cell recruitment to tumor, thus increasing the efficacy of 
a T cell-based immunotherapy approach (64). Furthermore, 
pharmacological blockade of tryptophan catabolism results 
in the control of tumor growth in a lymphocyte-dependent 
manner. Collectively, interfering with amino acid metabolism 
within tumors represents a very promising option to develop 
novel combination therapy in order to rouse dormant T cells 
and prompt them to efficiently sustain tumor eradication.
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